Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 13NETWORK 2OTHER_GOV 1NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 39Breast 10Gynecologic 3Endocrine 2Thoracic 1Head & Neck 1Genitourinary 1CNS 1

Conditions

Somatostatinoma 2Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Neuroendocrine 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Filgrastim 3Doxorubicin 3Temozolomide 2Octreotide 2Ifosfamide 2Etoposide 2Cisplatin 2Capecitabine 2vatalanib 1vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1telotristat ethyl 1pegfilgrastim 1motesanib diphosphate 1mercaptoundecahydrododecaborate 1lanreotide 1batifiban 1Suramin 1Radiotherapy 1Platinum 1Mitotane 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Gene Expression Profiling 1Everolimus 1Ethane 1Docetaxel 1Dichlorodiphenyldichloroethane 1DNA Methylation 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Capecitabine × Endocrine × Clear all
NCT02595424 2026-05-01

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
67 enrolled 13 charts
Endocrine

Somatostatinoma, Carcinoma, Neuroendocrine

NCT01824875 2026-02-25

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
144 enrolled 15 charts
Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡